Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 12/20 | 0.91 |
| ▸ | FGFR1 | P11362 | 5/20 | 0.91 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.91 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.91 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.91 |
| ▸ | STK10 | O94804 | 2/20 | 0.91 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.91 |
| ▸ | RET | P07949 | 2/20 | 0.91 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.91 |
| ▸ | DDR1 | Q08345 | 2/20 | 0.91 |
| ▸ | SLK | Q9H2G2 | 2/20 | 0.91 |
| ▸ | NUAK2 | Q9H093 | 1/20 | 0.91 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.84 |
| ▸ | KDR | P35968 | 16/20 | 0.77 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.77 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.77 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.77 |
| ▸ | ABL1 | P00519 | 1/20 | 0.77 |
| ▸ | EGFR | P00533 | 1/20 | 0.77 |
| ▸ | LCK | P06239 | 1/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Brivanib Alaninate SCHEMBL28365380 | 0.95 | CYP3A4 (1.00) | CYP3A4FGFR1CYP2D6CYP2C9CYP2C19 | |
| Brivanib Alaninate SCHEMBL29355920 | 0.95 | CYP3A4 (1.00) | CYP3A4FGFR1CYP2D6CYP2C9CYP2C19 | |
| Brivanib Alaninate SCHEMBL13108648 | 0.95 | CYP3A4 (1.00) | CYP3A4FGFR1CYP2D6CYP2C9CYP2C19 | |
| Brivanib Alaninate SCHEMBL2263525 | 0.95 | CYP3A4 (1.00) | CYP3A4FGFR1CYP2D6CYP2C9CYP2C19 | |
| Brivanib Alaninate SCHEMBL18319845 | 0.95 | CYP3A4 (1.00) | CYP3A4FGFR1CYP2D6CYP2C9CYP2C19 | |
| Brivanib Alaninate SCHEMBL29665039 | 0.95 | CYP3A4 (1.00) | CYP3A4FGFR1CYP2D6CYP2C9CYP2C19 | |
| Brivanib Alaninate SCHEMBL483382 | 0.95 | CYP3A4 (1.00) | CYP3A4FGFR1CYP2D6CYP2C9CYP2C19 | |
| Brivanib Alaninate SCHEMBL15971686 | 0.95 | CYP3A4 (1.00) | CYP3A4FGFR1CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL25448496 | 0.92 | CYP3A4 (0.83) | CYP3A4FGFR1CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL25450292 | 0.92 | CYP3A4 (0.83) | CYP3A4FGFR1CYP2D6CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7671199-B2 | Process for the preparation of [(1R), 2S]-2-aminopropionic acid 2-[4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2, 1-F][1,2,4]triazin-6-yloxy]-1-methylethyl ester | BRITSOL-MYERS SQUIBB COMPANY (US) | 2010-03-02 | — | — | US | disclosed |
| US-20070249610-A1 | PROCESS FOR THE PREPARATION OF [(1R), 2S]-2-AMINOPROPIONIC ACID 2-[4-(4-FLUORO-2-METHYL-1H-INDOL-5-YLOXY)-5-METHYLPYRROLO[2,1-f][1,2,4]TRIAZIN-6-YLOXY]-1-METHYLETHYL ESTER | BRISTOL-MYERS SQUIBB COMPANY | 2007-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070249610-A1 | PROCESS FOR THE PREPARATION OF [(1R), 2S]-2-AMINOPROPIONIC ACID 2-[4-(4-FLUORO-2-METHYL-1H-INDOL-5-YLOXY)-5-METHYLPYRROLO[2,1-f][1,2,4]TRIAZIN-6-YLOXY]-1-METHYLETHYL ESTER | ALDH7A1, MAT1A, IMPDH1 | CYP3A4 105/4885FGFR1 340/4885CYP2D6 457/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.